Acquisition Extends Digital Health Care from Augmented and Virtual Reality Glasses to Smartphone Apps, Smartwatches and IoT Devices, Combining AI and Licensed Clinicians to Deliver Continuous, Reimbursable Care for Chronic Conditions

July 15 2026 — XRHealth, the leading platform for therapeutic technologies, today announced the acquisition of Swing Therapeutics, a leading developer of digital therapies and the virtual care platform Swing Care for chronic pain conditions. The acquisition propels XRHealth as the largest extended reality digital health platform for chronic conditions, bringing digital healthcare seamlessly across multiple digital devices including augmented and virtual reality glasses, smart phone apps, smartwatches, and IoT wearables, combining AI and licensed physicians to treat patients across multiple technologies.

The acquisition adds Swing Therapeutics’ FDA De Novo–authorized Stanza program to XRHealth’s existing behavioral health and chronic pain capabilities, deepening the platform’s reach into two of the most undertreated conditions in the country: fibromyalgia and chronic pain.

“When we founded Swing, we believed that the future of chronic pain care had to look fundamentally different: more accessible, more personalized, and grounded in evidence,” says Mike Rosenbluth, Founder and CEO of Swing Therapeutics. “Joining XRHealth means we can deliver on that vision at an expanded scale, with clinicians and technology working together through a single platform where patients can access every dimension of their care.”

Swing Therapeutics’ Stanza is the first digital behavioral therapy indicated for treatment of the symptoms of fibromyalgia, a widespread chronic pain condition impacting 10 million people in the United States. In a Phase 3 randomized controlled trial published in The Lancet, Stanza demonstrated significant improvements across symptoms, including fibromyalgia severity, pain intensity, fatigue, sleep and depression.

The acquisition also brings Swing Care, Swing Therapeutics’ virtual specialty care platform for fibromyalgia and chronic pain, into the XRHealth ecosystem. Developed in collaboration with leading fibromyalgia clinicians, including Medical Director Dr. Andrea Chadwick, a globally recognized expert in the field, Swing Care delivers comprehensive, multidisciplinary care that combines the Stanza digital therapeutic with medication management, mental health support, and personalized coaching.

“The future of therapeutic care is technology. Not as a supplement to medicine, but as the medicine itself—delivered through AI, monitored by licensed clinicians, reimbursed by insurance, and continuously improved by outcomes data,” says Eran Orr, CEO of XRHealth. “The healthcare system has a supply and demand problem: too few clinicians, too many patients, and costs that are out of reach for most. Technology is how we solve that. XRHealth and Swing Therapeutics together represent the most comprehensive approach to this challenge ever assembled—spanning devices, apps, digital therapeutics, clinical care, and peer support, all in one platform. We are building the infrastructure for the next era of medicine.”

A Platform Built for the Whole Patient

Patients with chronic conditions have traditionally navigated a system that treats symptoms in isolation: one specialist, one prescription, one modality at a time. XRHealth’s platform transforms that approach, with a closed-loop therapeutic system that combines technology, artificial intelligence, and licensed clinicians to deliver continuous, personalized care for a variety of conditions and combines insights to treat the whole patient.

With the acquisition of Swing Therapeutics, XRHealth can now serve patients across physical, cognitive, and behavioral health with an unmatched depth of clinical evidence and breadth of therapeutic modalities.

The platform is informed by outcomes data, supervised by clinicians, and delivered in a reimbursable model. As new technologies demonstrate clinical value, they are incorporated and made available to patients through their insurance. The result is a platform defined not by what it sells, but by what it achieves — and one that becomes more powerful as it grows.

Proven at Scale, Built for Growth

Founded in 2019, Swing Therapeutics not only brings clinically-validated treatments but also strong commercial momentum and real-world outcomes. Thousands of patients have received high-quality treatment through Swing Care, a comprehensive virtual clinic for chronic pain treatment, with strong clinical outcomes. At the one-year mark, 88.0% of patients reported improvement in overall wellbeing (PGIC), with over half (50.2%) stating they felt “much improved” or better.

About XRHealth

XRHealth is the leading platform for therapeutic technologies, delivering FDA-registered immersive devices, evidence-based digital therapeutic programs, mobile care tools, and peer community support to patients living with chronic physical, cognitive, and behavioral health conditions. XRHealth is licensed across 22 U.S. states and serves patients through Medicare Part B, VA programs, and expanding commercial insurance pathways. Learn more at xr.health.

About Swing Therapeutics

Swing was founded in 2019 with the goal of developing evidence-based digital treatments and virtual care services to help people with chronic illness live their best lives. Swing Therapeutics developed the Stanza® program, an FDA De Novo–authorized prescription digital therapeutic for treatment of fibromyalgia symptoms in adult patients. Stanza is grounded in Acceptance and Commitment Therapy (ACT) and validated by a Phase 3 randomized controlled trial published in The Lancet.

Stanza is available by prescription through Swing Care, a specialty clinic that offers comprehensive treatment for fibromyalgia. Clinical guidelines were developed by Medical Director Dr. Andrea Chadwick, a globally recognized expert in fibromyalgia care. To learn more about Swing Care, visit swing.care

 




July 15 2026 – The World Health Organization (WHO) today released updated guidelines on reducing the risk of cognitive decline and dementia, providing countries with evidence-based recommendations to help prevent or delay the onset of dementia across the life course.

Dementia is a condition caused by brain diseases and affects memory, thinking and the ability to function. More than 57 million people live with dementia worldwide and nearly 10 million people get newly diagnosed every year. Alzheimer disease is the most common form of dementia and is estimated to account for 60–70% of cases.

While there is no cure for dementia, up to 45% of the risks can be attributed to modifiable risk factors such as tobacco, alcohol use, social isolation, physical inactivity, air pollution and noncommunicable diseases (NCDs), including high blood pressure and diabetes. Beyond health, dementia affects a person’s independence, dignity and safety.

“We know more today than ever before about what drives dementia risk, and these guidelines translate that knowledge into action,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Countries now have clear, evidence-based recommendations they can put into practice immediately to protect people’s cognitive health.”

WHO’s new guidelines reflect the latest evidence and innovations in dementia risk reduction providing proven interventions that can effectively lower dementia risk through early awareness and timely action. They represent an important opportunity to reduce the burden of dementia in the coming decades through stronger integration of services for noncommunicable diseases, mental health and brain health.

Reducing risk, preventing illness

The updated guidelines reflect significant growth in the evidence base since WHO first issued recommendations on dementia risk reduction in 2019. They provide consolidated recommendations on addressing unhealthy behaviours, managing medical conditions, and reducing exposure to environmental factors that may contribute to cognitive decline and dementia.

The guidelines recommend several healthy behaviours and lifestyle interventions to reduce dementia risk, including cognitive training and cognitive stimulation and engagement in social activities for adults who have normal cognition or are experiencing mild cognitive impairment.

The updated advice also includes interventions that reduce risk of NCDs, including increasing physical activity, stopping tobacco use, reducing alcohol consumption, adopting a healthy diet, and a new recommendation to reduce exposure to air pollution.

Management of cardiometabolic conditions such as hypertension, diabetes, and high cholesterol can also help reduce dementia risk. Further, hearing aids may be offered as part of risk-reduction strategies.

As an intervention to reduce the risk of cognitive decline and/or dementia, the guidelines do not recommend supplementation with vitamins B and E, omega-3 polyunsaturated fatty acids (PUFA) and multivitamins/minerals in the absence of a diagnosed deficiency, due to the lack of evidence of any potential benefits to outweigh unexpected harmful effects.

Human and economic cost

Dementia affects an individual’s ability to live independently, work and function, while placing substantial burdens on families and carers. It carries a major economic loss, costing the global economy an estimated US$1.3 trillion annually. About half of this cost is driven by unpaid care provided by families and friends. Understanding risk factors and taking action to prevent dementia can improve health and quality of life, helping people live longer, healthier and more independent lives.

Related links

Health topic page: Dementia

Factsheet: https://www.who.int/news-room/fact-sheets/detail/dementia




July 14, 2026 – Florida Neurology Group is expanding access to migraine and severe headache relief with the introduction of same-day headache infusion treatments at its Fort Myers office, offering patients a faster alternative to emergency room or urgent care visits.

 

The new service, launched this spring, provides patients with access to advanced intravenous and intramuscular treatments traditionally administered in hospital settings. While the medications and protocols have long been used in emergency care, they are rarely available in outpatient neurology practices.

 

“Very few neurology practices across the country offer this level of treatment in an office setting,” said Dr. Anthony C. Brown, a neurologist and headache specialist at Florida Neurology Group. “Our goal is to expand access and provide meaningful relief for patients as quickly as possible, without requiring a trip to the emergency room.”

 

Florida Neurology Group’s infusion protocols, developed by Brown, use carefully managed combinations of medications designed to treat acute migraine and headache symptoms.

 

Offering these treatments in an outpatient setting requires specialized storage, handling and administration capabilities, which can be a barrier for many providers.  As a result, patients often have limited options outside of emergency care when experiencing debilitating migraines.

 

“Severe headaches and migraines shouldn’t keep patients from living their lives,” Brown said. “By offering same-day treatment, we’re able to reduce symptom severity and help people get back to the activities they enjoy.”

 

By providing these services locally, Florida Neurology Group aims to reduce unnecessary emergency visits, helping patients save time and potentially lower healthcare costs while receiving specialized neurological care.

 

For more information about migraine treatment options or to schedule an appointment, visit fngmd.com/migraines.

 

About Florida Neurology Group

 

Florida Neurology Group is a leading provider of neurological care in Southwest Florida, offering comprehensive diagnosis and treatment for a wide range of neurological conditions, including migraines, epilepsy and movement disorders. With a team of experienced specialists and a patient-centered approach, Florida Neurology Group is committed to advancing care through innovative treatments and accessible services. For more information, please visit fngmd.com.




July 14 2026 – The Centers for Medicare & Medicaid Services (CMS) is proposing transformational reforms to Medicare’s physician payment and value-based care programs that would expand accountable care, modernize physician payment, reduce administrative burden, and help shift the healthcare system’s focus from treating illness to preventing it.

The proposals would make Medicare accountable care organizations (ACOs) easier to join and more rewarding to participate in, transition clinicians away from traditional Merit-based Incentive Payment System (MIPS) reporting toward more meaningful value-based care pathways, and update physician payment policies to better reflect modern clinical practice. Together, these reforms would strengthen primary care, improve patient outcomes, and support Medicare’s long-term sustainability.

“We’re proposing some of the most significant Medicare reforms in recent years to strengthen primary care, expand accountable care, and modernize physician payment,” said CMS Administrator Dr. Mehmet Oz. “These changes would make it easier for clinicians to focus on prevention, improve coordination for patients, and ensure Medicare rewards better outcomes rather than more services.”

“Expanding accountable care is a critical part of making the Medicare program work well for patients,” said John Brooks, CMS Deputy Administrator and Director of the Center for Medicare. “Our goal is simple: deliver better outcomes for patients by appropriately incentivizing providers, improving quality measurement, and reducing administrative burden.”

Strengthening Medicare ACO Participation and Accountability

CMS is proposing significant improvements to the Medicare Shared Savings Program (Shared Savings Program), the nation’s largest value-based payment program. The proposed changes would support continued participation and growth in accountable care, while strengthening incentives for high-quality, coordinated care.

ACOs are a key part of the Administration’s efforts to strengthen primary care, improve preventive services, and help people with Original Medicare live healthier lives through better coordinated care. ACOs are groups of doctors, hospitals, and other healthcare providers who work together to coordinate care for people with Original Medicare. Their focus on prevention, care management, and patient engagement has produced measurable results for patients and taxpayers alike.

Patients receiving care from ACO healthcare providers are more likely to receive preventive services and screenings and less likely to experience uncontrolled chronic conditions such as diabetes and high blood pressure. ACOs also help reduce unnecessary spending by incentivizing healthcare providers to use healthcare resources more efficiently.

The Shared Savings Program has already demonstrated strong financial results. In performance year 2024, 75% of the 476 participating ACOs earned shared savings payments totaling $4.1 billion. Even after those payments, net savings of approximately $2.5 billion compared to projected spending benchmarks were generated for the Medicare Trust Funds. The Shared Savings Program has now generated savings for the Medicare Trust Funds for eight consecutive performance years. The proposed rule would build on this record by improving benchmark accuracy, supporting continued and expanded participation, and reducing unnecessary administrative burden.

The Shared Savings Program proposals would:

  • Increase opportunities to share savings for certain participating ACOs.
  • Create new financial incentives for organizations joining the program for the first time.
  • Establish more predictable spending targets to improve planning and participation.
  • Reduce administrative burden by simplifying technology requirements and streamlining patient notices.
  • Allow ACOs with approved applications beginning April 1, 2027, to reduce or eliminate beneficiary out-of-pocket costs for certain items and services, expanding a successful approach already adopted by many participants in the ACO REACH Model.

Modernizing Medicare Physician Payments

CMS is also proposing updates to the Physician Fee Schedule (PFS) to better reflect modern medical practice and support the Trump administration’s goal of shifting from sick care to healthcare.

Over time, the PFS has accumulated layers of outdated payment policies and billing conventions that no longer fully reflect how healthcare services are delivered. CMS is proposing a targeted recalibration of payment rates to improve accuracy, transparency, and consistency.

The proposed changes would:

  • Better align payments with the time, resources, and complexity involved in delivering care.
  • Account for efficiencies that occur when multiple services are delivered during the same patient encounter.
  • Improve oversight of billing practices and address areas where claims may not accurately reflect services provided.
  • Increase transparency into how physician payment rates are calculated.

As CMS works to shift the health system’s focus from treating illness to preventing it, accurate payment policies are essential to supporting better patient outcomes. By ensuring payment incentives reflect modern clinical practice, the agency aims to encourage the right care at the right time while maintaining stewardship of Medicare resources.

Advancing the Next Generation of Quality Reporting and Value-Based Care

CMS is also proposing to sunset traditional Merit-based Incentive Payment System (MIPS) reporting in 2029 and transition clinicians toward more clinically meaningful specialty-focused MIPS Value Pathways (MVPs).

When MIPS was launched in 2017, its goal was to move Medicare away from a fragmented fee-for-service system toward one that rewards quality, outcomes, and value. Over the past decade, CMS has worked with clinicians to refine the program and reduce reporting burden. The proposed rule reflects that evolution by establishing MIPS Value Pathways (MVPs), as the primary reporting option in MIPS.

Beginning with the 2029 performance period, traditional MIPS would sunset, marking the next phase in Medicare’s transition toward value-based care. MIPS eligible clinicians would have until the end of 2028 to transition to an MVP unless they participate in a MIPS APM and report the APM Performance Pathway (APP).

CMS is proposing three new MVPs focused on diabetes, hypertension, and hospital-based care to further expand participation opportunities and promote prevention. If finalized, the MVPs inventory would provide a relevant reporting option for approximately 98% of specialties.

The proposal also would introduce new MIPS Core Measures beginning in 2027. Under this approach, every clinician would report at least one measure considered fundamental to their specialty and patient population. The goal is to improve consistency and generate more meaningful quality data for patients, providers, and policymakers.

In addition, CMS is proposing to reform how it pays the APM incentive payment to close a payment loophole that could otherwise result in an estimated $2.38 billion in windfall payments to clinicians who do not participate in APMs over the next decade, helping ensure incentives are directed to providers actively delivering value-based care and improving patient outcomes.

Putting Patients and Providers First

Together, these proposals represent one of the most significant Medicare modernization efforts in recent years, expanding accountable care, modernizing physician payment, reducing administrative burden, and helping Medicare deliver better outcomes for beneficiaries while preserving the program’s long-term sustainability.

The proposed rule is open for public comment, and CMS encourages stakeholders across the healthcare system to provide feedback.

To view the proposed rule, please visit: https://www.federalregister.gov/public-inspection/current

View the related Quality Payment Program fact sheet at: https://d2g5m5leph8kam.cloudfront.net/s3fs/s3fs-public/2026-06/2027-qpp-proposed-rule-factsheet.pdf?VersionId=R3HfF.xfEIgdOmJuJYIOgToEwLFDPYjW

For a fact sheet on the CY 2027 Physician Fee Schedule proposed rule, please visit: https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2027-medicare-physician-fee-schedule-proposed-rule

For a fact sheet on the proposed Medicare Shared Savings Program changes in the CY 2027 PFS proposed rule, please visit: https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2027-medicare-physician-fee-schedule-proposed-rule-cms-1848-p-medicare-shared




July 14 2026 – Sisters Dr. Annabelle Menendez and Dr. Katherine Menendez share a special bond following in the footsteps of their father who was a physician practicing family medicine in Miami. They celebrated that bond in a touching moment during Broward Health’s annual Graduate Medical Education (GME) White Coat Ceremony.

It was older sister, Katherine, who placed the traditional white coat on Annabelle marking the next step in her medical career as she begins a three-year residency in family medicine at Broward Health. Meanwhile Katherine is now completing her own family medicine residency, serving as Broward Health’s chief resident.

“This is such a meaningful milestone for our family,” Annabelle said. “It is an honor for both my sister and me to follow in the path of our father who had an incredible influence on us, leading us both to where we are today. I am forever grateful to him and my sister.”

Annabelle was part of the Broward Health Graduate Medical Education (GME) incoming class of 141 residents and fellows, the largest GME class in the healthcare system’s history. She is one of 388 Broward Health residents and fellows across 28 residency and fellowship programs, including cardiovascular, emergency medicine, pediatrics and more who rotate throughout Broward Health facilities as part of their training experience.

Broward Health now has 28 residency and fellowship programs across the system: 24 are ACGME accredited residency and fellowship programs; one is a CODA accredited OMFS program; and three are ASHP accredited pharmacy residency programs. There are 16 programs at Broward Health North, including the launch this year of the obstetrics and gynecology and pharmacy programs. There are 11 programs at Broward Health Medical Center and one program at Broward Health Imperial Point.

About Broward Health

Broward Health, founded in 1938 and headquartered in Fort Lauderdale, Florida, ranks among the 10 largest public healthcare systems in the United States. Nationally recognized for its focus on high-quality care for the residents of Broward County and beyond, Broward Health boasts four hospitals, two trauma centers, was the county’s first statutory teaching hospital and has an ever-growing graduate medical education program. It includes more than 50 health centers and physician practices covering virtually every healthcare specialty.

Broward Health never stops working toward its mission of Exceptional Care, Extraordinary Compassion and Everyday Excellence. Driven by more than 11,000 talented employees and physicians who deliver care to all patients, regardless of their ability to pay, Broward Health is one of the largest employers in Broward County with an operating budget of over $2 billion and annually provides over $523 million in charity and uncompensated care.

For more information about Broward Health, visit BrowardHealth.org.